ATXS · As filed with the SEC
Astria Therapeutics balance sheet, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 |
|---|---|---|---|---|
| Statement | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 59,820,000 | 175,530,000 | 20,525,000 | 86,508,000 |
| Short-term investments | 268,312,000 | 71,000,000 | 205,912,000 | 39,000,000 |
| Prepaid expenses and other current assets | 6,511,000 | 4,412,000 | 1,253,000 | 1,567,000 |
| Total current assets | 334,643,000 | 250,942,000 | 227,690,000 | 127,075,000 |
| Right-of-use asset | 5,114,000 | 363,000 | 948,000 | 394,000 |
| Other assets | 2,606,000 | 3,361,000 | 1,995,000 | 45,000 |
| Total assets | 342,363,000 | 254,666,000 | 230,633,000 | 127,514,000 |
| Liabilities and stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | 4,320,000 | 1,513,000 | 788,000 | 1,557,000 |
| Accrued expenses | 13,427,000 | 9,708,000 | 7,690,000 | 3,281,000 |
| Current portion of operating lease liabilities | 1,384,000 | 329,000 | 582,000 | 365,000 |
| Total current liabilities | 19,131,000 | 11,550,000 | 9,060,000 | 5,203,000 |
| Long-term portion of operating lease liabilities | 3,969,000 | — | 357,000 | — |
| Total liabilities | 23,100,000 | 11,550,000 | 9,417,000 | 5,203,000 |
| Stockholders' equity: | ||||
| Series X Preferred Stock | — | — | — | 96,398,000 |
| Common stock, $0.001 par value per share, 150,000,000 shares authorized; 56,434,219 and 41,034,797 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 57,000 | 41,000 | 28,000 | 13,000 |
| Additional paid-in capital | 898,513,000 | 728,285,000 | 632,512,000 | 481,709,000 |
| Accumulated other comprehensive gain | 163,000 | — | (79,000) | — |
| Accumulated deficit | (674,794,000) | (580,534,000) | (507,643,000) | (455,809,000) |
| Total stockholders' equity | 319,263,000 | 243,116,000 | 221,216,000 | 122,311,000 |
| Total liabilities and stockholders' equity | 342,363,000 | 254,666,000 | 230,633,000 | 127,514,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.